TA198

Rheumatoid arthritis - tocilizumab (TA198) (replaced by TA247)

  • Technology appraisals TA198
  • Issued: August 2010
    • Tocilizumab for rheumatoid arthritis

      This guidance has been replaced by TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198)

      NICE recommends tocilizumab, taken with a drug called methotrexate, as a possible treatment for some people with rheumatoid arthritis.

      Who can have tocilizumab?

      You should be able to have tocilizumab if:

      • you have moderate to severe active rheumatoid arthritis and
      • you have tried at least one drug called a tumour necrosis factor alpha (or TNF-Ã?± for short) inhibitor and a drug called rituximab but these have not worked.

      If you cannot take rituximab for medical reasons or you had to stop taking it because you had a bad reaction to it, you should still be able to have tocilizumab if you have moderate to severe active rheumatoid arthritis and have tried at least one drug called a TNF-Ã?± inhibitor.

      Why has NICE said this?

      NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended tocilizumab in these circumstances because it works well and its cost is justified after other drugs that are likely to be equally effective and cheaper to give have been tried.

      This page was last updated: 14 February 2012

    • Guidance formats

      Query

Implementation tools and resources

  • None available

See this guidance in practice

Patient

The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.

Quick Reference Guide

The quick reference guide presents recommendations for health professionals

NICE Guidance

The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.

Full Guidance

The published full clinical guidance for specialists with background, evidence, recommendations and methods used.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.